Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Prognostic and predictive factors for overall survival in metastatic oesophagogastric cancer: A systematic review and meta-analysis
Emil ter Veer, Jessy Joy van Kleef, Sandor Schokker, et al.
European Journal of Cancer (2018) Vol. 103, pp. 214-226
Closed Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma
M.J.M. van Velzen, Sarah Derks, Nicole C.T. van Grieken, et al.
Cancer Treatment Reviews (2020) Vol. 86, pp. 102024-102024
Open Access | Times Cited: 129
Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: A systematic review and meta-analysis
Tiuri E. Kroese, Hanneke W.M. van Laarhoven, Magnus Nilsson, et al.
European Journal of Cancer (2022) Vol. 166, pp. 254-269
Open Access | Times Cited: 70
Incidence and survival of patients with oligometastatic esophagogastric cancer: A multicenter cohort study
Tiuri E. Kroese, Sebastian M. Christ, Peter S.N. van Rossum, et al.
Radiotherapy and Oncology (2022) Vol. 173, pp. 269-276
Open Access | Times Cited: 33
The Use of (Network) Meta-Analysis in Clinical Oncology
Emil ter Veer, Martijn G.H. van Oijen, Hanneke W.M. van Laarhoven
Frontiers in Oncology (2019) Vol. 9
Open Access | Times Cited: 53
Heterogeneity of first‐line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: A real‐world evidence study
Willemieke P.M. Dijksterhuis, Rob H.A. Verhoeven, Marije Slingerland, et al.
International Journal of Cancer (2019) Vol. 146, Iss. 7, pp. 1889-1901
Open Access | Times Cited: 40
Tislelizumab versus chemotherapy as second-line treatment of advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302): impact on health-related quality of life
Eric Van Cutsem, Kazuaki Kato, Jaffer A. Ajani, et al.
ESMO Open (2022) Vol. 7, Iss. 4, pp. 100517-100517
Open Access | Times Cited: 20
Circulating tumor DNA predicts outcome in metastatic gastroesophageal cancer
M.J.M. van Velzen, Aafke Creemers, Tom van den Ende, et al.
Gastric Cancer (2022) Vol. 25, Iss. 5, pp. 906-915
Open Access | Times Cited: 19
The association between wearable activity monitor metrics and performance status in oncology: a systematic review
Milan Kos, Esther N. Pijnappel, Laurien M. Buffart, et al.
Supportive Care in Cancer (2021) Vol. 29, Iss. 11, pp. 7085-7099
Open Access | Times Cited: 21
CT-Based Radiomic Score: A Risk Stratifier in Far-Advanced Gastric Cancer Patients
Lan Wang, Lan Zhu, Jun Yan, et al.
Academic Radiology (2023) Vol. 30, pp. S220-S229
Open Access | Times Cited: 8
SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer
Héctor van den Boorn, Ameen Abu‐Hanna, Emil ter Veer, et al.
Cancers (2019) Vol. 11, Iss. 2, pp. 187-187
Open Access | Times Cited: 23
Clinical scoring system for the prediction of survival of patients with advanced gastric cancer
Jinchul Kim, Jung Yong Hong, Seung Tae Kim, et al.
ESMO Open (2020) Vol. 5, Iss. 2, pp. e000670-e000670
Open Access | Times Cited: 21
Prognostic values of myosteatosis for overall survival in patients with gastric cancers: A meta-analysis with trial sequential analysis
Te Fang, Yang Gong, Yue Wang
Nutrition (2022) Vol. 105, pp. 111866-111866
Closed Access | Times Cited: 13
Effects of sintilimab plus chemotherapy as first-line treatment on health-related quality of life in patients with advanced esophageal squamous cell carcinoma: results from the randomized phase 3 ORIENT-15 study
Zhihao Lü, Li Kong, Buhai Wang, et al.
EClinicalMedicine (2024) Vol. 72, pp. 102623-102623
Open Access | Times Cited: 2
Prognostic value of patient-reported quality of life for survival in oesophagogastric cancer: analysis from the population-based POCOP study
Jessy Joy van Kleef, Willemieke P.M. Dijksterhuis, Héctor G. van den Boorn, et al.
Gastric Cancer (2021) Vol. 24, Iss. 6, pp. 1203-1212
Open Access | Times Cited: 15
Prognostic value of pre-therapeutic FDG-PET radiomic analysis in gastro-esophageal junction cancer
Karim Amrane, Philippe Thuillier, David Bourhis, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 6
Liver oligometastatic disease in synchronous metastatic gastric cancer patients: a nationwide population-based cohort study
Tiuri E. Kroese, Yuko Takahashi, Florian Lordick, et al.
European Journal of Cancer (2022) Vol. 179, pp. 65-75
Open Access | Times Cited: 9
Stereotactic radiotherapy or metastasectomy for oligometastatic esophagogastric cancer: A nationwide population-based cohort study
Tiuri E. Kroese, Nikita K. N. Jorritsma, Hanneke W.M. van Laarhoven, et al.
Clinical and Translational Radiation Oncology (2022) Vol. 37, pp. 109-115
Open Access | Times Cited: 8
The Prognostic Role of Early Skeletal Muscle Mass Depletion in Multimodality Management of Patients with Advanced Gastric Cancer Treated with First Line Chemotherapy: A Pilot Experience from Modena Cancer Center
Margherita Rimini, Annarita Pecchi, F. Prampolini, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 8, pp. 1705-1705
Open Access | Times Cited: 8
Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB)
Esther N. Pijnappel, J. Annelie Suurmeijer, Bas Groot Koerkamp, et al.
JAMA Oncology (2022) Vol. 8, Iss. 6, pp. 929-929
Open Access | Times Cited: 6
External Validation of the Dutch SOURCE Survival Prediction Model in Belgian Metastatic Oesophageal and Gastric Cancer Patients
Jessy Joy van Kleef, Héctor G. van den Boorn, Rob H.A. Verhoeven, et al.
Cancers (2020) Vol. 12, Iss. 4, pp. 834-834
Open Access | Times Cited: 7
Informing Patients With Esophagogastric Cancer About Treatment Outcomes by Using a Web-Based Tool and Training: Development and Evaluation Study
Loïs F van de Water, Héctor G. van den Boorn, Florian Hoxha, et al.
Journal of Medical Internet Research (2021) Vol. 23, Iss. 8, pp. e27824-e27824
Open Access | Times Cited: 7
Effect of a prediction tool and communication skills training on communication of treatment outcomes: a multicenter stepped wedge clinical trial (the SOURCE trial)
Loïs F van de Water, Steven C. Kuijper, Inge Henselmans, et al.
EClinicalMedicine (2023) Vol. 64, pp. 102244-102244
Open Access | Times Cited: 2
Tislelizumab in advanced/metastatic esophageal squamous cell carcinoma: health-related quality of life in Asian patients
Sung‐Bae Kim, Eric Van Cutsem, Jaffer A. Ajani, et al.
Current Medical Research and Opinion (2023) Vol. 40, Iss. 1, pp. 69-75
Open Access | Times Cited: 2
Mandatory Reporting Measurements in Trials for Potentially Resectable Pancreatic Cancer
Esther N. Pijnappel, J. Annelie Suurmeijer, Bas Groot Koerkamp, et al.
Springer eBooks (2021), pp. 107-118
Closed Access | Times Cited: 3
The association between effectiveness of first-line treatment and second-line treatment in gastro-oesophageal cancer
M.J.M. van Velzen, Marieke Pape, Willemieke P.M. Dijksterhuis, et al.
European Journal of Cancer (2021) Vol. 156, pp. 60-69
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top